Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO

Vortex Biosciences, the cancer diagnosis biotechnology business, has announced the appointment of Dr Adrian Kinkaid as its new Chief Executive Officer.


News provided by

Vortex Biosciences

Jun 02, 2021, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO
Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO

LONDON, June 2, 2021 /PRNewswire-PRWeb/ -- Vortex Biosciences has developed the VTX-1, a best-in-class instrument that isolates and purifies Circulating Tumor Cells (CTCs) from blood. These cells can then be used for cancer diagnosis and monitoring, research on drug development, cancer research and development of personalized medicine.

Dr Adrian Kinkaid joins Vortex Biosciences on contract, alongside his other roles as CEO of healthcare diagnostic biotech BioFab Ltd and antibody testing biotech Lumabs BV. A specialist in leading early-stage start-ups, Adrian has led several funding rounds for MIP Diagnostics, a synthetic antibody biotech, where he served as CEO for four years until 2019. He has also secured non-dilutive funding for MIP Diagnostics and BioFab via the prestigious SMART Awards.

We are delighted to welcome Adrian. His experience in commercializing game changing medical technologies will help execute Vortex’s ambitious plans in the rapidly growing liquid biopsy market. Following EMV Capital's trans-Atlantic strategy, Vortex operates out of the Bay Area and in Cambridge, UK

Post this

Prior to this, he was Chief Commercial Officer for Promexus, a protein biotherapeutics company based on Affimer technology, and Strategic Market Development Leader for Abcam, the leading provider of research antibodies. He has a particular passion for improving patient outcomes and game-changing new technologies, especially in the in vitro diagnostics space.

As CEO, Dr Adrian Kinkaid will be overseeing the operations of Vortex Biosciences across its two sites in San Francisco, US and Cambridge, UK. He will be working closely with the board as well as Dr. Ilian Iliev, the Executive Chairman. Adrian will be using his expertise and experience to help Vortex Biosciences commercialize its medical technologies and grow rapidly in the liquid biopsy market.

On his appointment, Dr Adrian Kinkaid said:
"I am delighted to be joining the Vortex Biosciences team. Vortex is in an unrivalled position with outstanding core technology and a best-in-class platform to provide Circulating Timor Cells (CTCs) with remarkable efficiency and purity. More importantly, Vortex's VTX-1 platform is providing game-changing opportunities for CTC isolation in the liquid biopsy market."

Vortex Biosciences Executive Chairman and NetScientific PLC CEO Dr. Ilian Iliev commented:
"We are delighted to welcome Adrian to the team at this critical juncture. We trust Adrian's experience in commercializing game-changing medical technologies will help execute Vortex's ambitious plans in the rapidly growing liquid biopsy market. Vortex is now based in two of the world's greatest biotech clusters – the Bay Area and Cambridge, UK – and is therefore well positioned to exploit the rapid growth in the liquid biopsy market on both sides of the Atlantic."

Adrian has a PhD in Biochemistry from the University of Southampton, centred on novel assay development, and undertook a post-doctoral position with the Institute of Cancer Research, London. His industrial experience started with agrochemical and pharmaceutical discovery where he developed a range of different biochemical and cell-based assays mainly for high throughput screening applications.

Adrian was also a Founding Member of European Laboratory Research and Innovation Group, a not-for-profit organization that holds conferences and events for thought leadership in the life science and drug discovery communities. He served two terms as Chairman, during which time he established the flagship Drug Discovery event, which is now the leading conference of its kind in Europe.

About Vortex Biosciences
http://www.vortexbiosciences.com

Vortex Biosciences provides an automated, label-free, benchtop solution for isolation and purification of Circulating Tumor Cells (CTCs) from a standard 8 ml tube of blood. The VTX-1 instrument rapidly processes the sample through micro vortices to enrich the CTCs and delivers these highly purified cells into a choice of collection formats. These samples containing viable, undamaged CTCs are easily integrated into downstream genomics, protein markers testing, single cell analysis and staining techniques. Vortex Biosciences was spun-out of UCLA, is backed by EMV Capital, a subsidiary of NetScientific PLC, and other private investors, and is dually based in San Francisco, USA and Cambridge, UK.

About EMV Capital
http://www.emvcapital.com

EMV Capital Ltd (EMVC) is a London-based award-winning investor focused on B2B companies in the healthcare, sustainability and industrials sectors. It is a subsidiary of AIM-listed NetScientific PLC. EMVC's investments in UK, US and Israel cover a range of technologies including robotics and AI, advanced engineering, power electronics and Medtech. EMVC's model is to develop customized investment strategies for its portfolio companies, combining its network of private investors, institutional VCs investors and Corporate VC funds.

EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

For more information, please visit https://www.vortexbiosciences.com

About NetScientific PLC

AIM-listed NetScientific Plc is a life sciences and sustainability technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value. For more information, please visit the website at https://netscientific.net/

Contact Information
EMV Capital Ltd | http://www.emvcapital.com
Dr. Ilian Iliev, Managing Director
[email protected]
+44 (0)203 761 6138

Vortex Biosciences, Inc | http://www.vortexbiosciences.com
Dr. Adrian Kinkaid, CEO
[email protected]
+1-650-252-2262

Media Contact

Dr. Ilian Iliev, Managing Director, EMV Capital, +44 2037616138, [email protected]

Dr. Adrian Kinkaid, CEO, Vortex Biosciences, +1-650-252-2262, [email protected]

SOURCE Vortex Biosciences

Related Links

https://vortexbiosciences.com/

Modal title

Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO
View PDF
Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO
Vortex Biosciences, liquid biopsy for cancer diagnosis, announces experienced start-up leader Dr. Adrian Kinkaid as new CEO

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.